<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:regsci-ojs-tamu.tdl.org:article/307</identifier>
				<datestamp>2025-08-15T19:46:51Z</datestamp>
				<setSpec>regsci:PC</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Regulatory Stringency and Impacts on Equity and Innovation in Medical Devices: Insights from the EU MDR 2017 and Considerations for the FDA</dc:title>
	<dc:creator xml:lang="en">Thottunkal, Stefan</dc:creator>
	<dc:subject xml:lang="en">AI Regulations</dc:subject>
	<dc:subject xml:lang="en">EU MDR</dc:subject>
	<dc:subject xml:lang="en">FDA</dc:subject>
	<dc:subject xml:lang="en">Regulation</dc:subject>
	<dc:subject xml:lang="en">Governance</dc:subject>
	<dc:subject xml:lang="en">Innovation</dc:subject>
	<dc:subject xml:lang="en">Medical Innovation</dc:subject>
	<dc:subject xml:lang="en">Medical Device</dc:subject>
	<dc:subject xml:lang="en">Small and medium-sized enterprises </dc:subject>
	<dc:subject xml:lang="en">Orphan Devices</dc:subject>
	<dc:subject xml:lang="en">Market Access</dc:subject>
	<dc:subject xml:lang="en">Patient Safety</dc:subject>
	<dc:subject xml:lang="en">Device Safety</dc:subject>
	<dc:subject xml:lang="en">AI</dc:subject>
	<dc:subject xml:lang="en">AI-enabled devices</dc:subject>
	<dc:subject xml:lang="en">Algorithmic Fairness</dc:subject>
	<dc:subject xml:lang="en">Regulations for Medical Devices </dc:subject>
	<dc:subject xml:lang="en">FDA Approvals</dc:subject>
	<dc:subject xml:lang="en">EU Regulatory Approvals</dc:subject>
	<dc:description xml:lang="en">The new EU Medical Device Regulations (MDR), originally put forth in 2017, aimed to improve medical device safety in light of regulatory failures. However, although the MDR have improved safety requirements, they have inadvertently created barriers for innovation which have disproportionately impacted small and medium-sized enterprises (SMEs) and orphan device manufacturers. This commentary explores the unintended consequences of the EU MDR as a cautionary case study for the U.S. Food and Drug Administration (FDA), emphasizing the need to balance regulations. In particular, this commentary discusses the mechanisms by which increased evidence requirements, extended approval timelines, and increased costs have led to market contraction which threaten patient health. Creative solutions are proposed including provisional approvals, subsidized applications, and international recognition agreements. The implications and precedent set by the MDR are used to forewarn emerging regulations in artificial intelligence-enabled medical devices.</dc:description>
	<dc:publisher xml:lang="en">Office of the Texas State Chemist</dc:publisher>
	<dc:date>2025-08-15</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://regsci-ojs-tamu.tdl.org/regsci/article/view/307</dc:identifier>
	<dc:identifier>10.21423/JRS.REGSCI.131307</dc:identifier>
	<dc:source xml:lang="en">Journal of Regulatory Science; Vol. 13 No. 1 (2025)</dc:source>
	<dc:source>2377-3537</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://regsci-ojs-tamu.tdl.org/regsci/article/view/307/342</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2025 Stefan Thottunkal</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
	
